CD8A and neoplasm: More interestingly, the same group showed earlier that GCS-100, a polysaccharide specific inhibitor of Gal-3, detached Gal-3 from CD8+ TIL and boosts their IFN-γ secretion and cytotoxic functions and promoted tumor rejection in mice models [125].